💊 Estradiol (Estradiol)
Estradiol transdermal system is an estrogen hormone patch designed to release estradiol continuously through intact skin. It is used to treat moderate to severe menopausal symptoms and hypoestrogenism, and to prevent postmenopausal osteoporosis. The dose and duration are set by your doctor only.
In Arabic: إستراديول (لصقة عبر الجلد)🏷️ Brand names & manufacturers
Lyllana🏭 Amneal Pharmaceuticals LLCDailyMed
Estring🏭 Pfizer Laboratories Div Pfizer IncDailyMed
Climara🏭 Bayer HealthCare Pharmaceuticals Inc.DailyMed
Yuvafem🏭 Amneal Pharmaceuticals LLCDailyMed
Estradiol Vaginal🏭 Encube Ethicals, Inc.DailyMed
Estradiol🏭 Alvogen Inc.DailyMed✅ What it is used for
- Treatment of moderate to severe vasomotor symptoms (such as hot flashes) due to menopause
- Treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause (topical vaginal products should be considered first if this is the only indication)
- Treatment of hypoestrogenism due to hypogonadism, castration, or primary ovarian failure
- Prevention of postmenopausal osteoporosis (non-estrogen medications should be considered first; estrogen is considered only for women at significant risk of osteoporosis)
🧪 Active ingredient
The active ingredient is estradiol, the principal intracellular human estrogen. It binds to estrogen receptors in estrogen-responsive tissues and reduces the elevated LH and FSH levels seen after menopause.
🌿 Benefits
- Relief of hot flashes and other menopausal symptoms
- Relief of vulvar and vaginal atrophy symptoms
- Replacement of estrogen in hypogonadism or ovarian failure
- Prevention of postmenopausal osteoporosis
📝 How to use
- Your doctor or pharmacist determines the dose and duration; do not change it without consulting them
- Apply to a clean, dry area of the lower abdomen or buttocks
- Do not apply to the breasts
- Applied twice weekly as directed by your doctor
- Apply immediately after removing from the protective pouch
- In women with a uterus, a progestogen may be added to reduce endometrial cancer risk, and the patch may be used on a cyclic schedule (e.g., 3 weeks on, 1 week off)
- Need for treatment should be reassessed periodically with your doctor
💊 Dosage forms
- Transdermal system 0.025 mg/day
- Transdermal system 0.0375 mg/day
- Transdermal system 0.05 mg/day
- Transdermal system 0.075 mg/day
- Transdermal system 0.1 mg/day
⚠️ Common side effects
- Headache
- Breast tenderness
- Nasopharyngitis
- Sinusitis and sinus headache
- Upper respiratory tract infection
- Back pain
- Depression
- Irregular vaginal bleeding or spotting
🚨 Serious — seek medical help
- Stroke
- Deep vein thrombosis and pulmonary embolism
- Myocardial infarction (heart attack)
- Endometrial cancer with estrogen-alone therapy in women with a uterus
- Breast cancer
- Probable dementia in women aged 65 and older
- Gallbladder disease
- Severe hypercalcemia, loss of vision, severe hypertriglyceridemia, or cholestatic jaundice (estrogen should be discontinued)
⛔ Do not use if
- Undiagnosed abnormal genital bleeding
- Breast cancer or a history of breast cancer
- Estrogen-dependent neoplasia
- Active DVT or PE, or a history of these
- Active arterial thromboembolic disease (e.g., stroke, MI) or a history of these
- Known anaphylactic reaction, angioedema, or hypersensitivity to the product
- Hepatic impairment or disease
- Protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders
❗ Warnings & precautions
- Boxed warning: increased risk of endometrial cancer, cardiovascular disorders, probable dementia, and breast cancer
- Do not use estrogen-alone therapy for the prevention of cardiovascular disease or dementia
- Use the lowest effective dose for the shortest duration consistent with treatment goals
- Discontinue immediately if stroke, DVT, PE, or MI occurs or is suspected
- Adequate diagnostic evaluation is needed for persistent or recurring undiagnosed abnormal genital bleeding
- Monitor thyroid function in women on thyroid replacement therapy
- Used patches still contain active hormone
🔄 Drug interactions
- CYP3A4 inducers (e.g., St. John's wort preparations, phenobarbital, carbamazepine, rifampin) may reduce estrogen levels, possibly decreasing effect and changing the uterine bleeding profile
- CYP3A4 inhibitors (e.g., erythromycin, clarithromycin, ketoconazole, itraconazole, ritonavir, grapefruit juice) may increase estrogen levels and may cause adverse reactions
- Tell your doctor or pharmacist about all medicines and herbal products you use
🤰 Pregnancy
The patch is not indicated for use in pregnancy. There are no data on its use in pregnant women.
🍼 Breastfeeding
Estrogens are present in human milk and can reduce milk production. The benefits of breastfeeding should be weighed against the mother's clinical need for the drug and any potential effects on the infant; consult your doctor.
🧒 Children
Not indicated for pediatric patients; clinical studies have not been conducted. If estrogen is given to patients whose bone growth is incomplete, periodic monitoring of bone maturation is recommended.
👴 Older adults
There are not enough data to determine whether women over 65 respond differently. WHI studies showed a higher relative risk of stroke, invasive breast cancer, and probable dementia in older women.
🌡️ Storage
Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C. Do not store unpouched. Apply immediately upon removal from the pouch. To discard a used patch, fold the sticky sides together, place it in a sturdy child-proof container, and put it in the trash. Do not flush in the toilet.
⏰ Missed dose
The label text provided gives no specific missed-dose instructions. Consult your doctor or pharmacist and do not double the dose on your own.
🆘 Overdose
Overdose may cause nausea, vomiting, breast tenderness, abdominal pain, drowsiness and fatigue, and withdrawal bleeding may occur. Treatment is discontinuation of the patch with appropriate symptomatic care. Seek medical help immediately.
💰 Price & brands in your area
Local prices are currently available for Palestine; more countries are coming. Ask your pharmacist for local price and alternatives.
📍 Find the nearest pharmacy
Your location is used only in your browser to show nearby pharmacies — we don't store it.
Open in Google Maps👨⚕️ For healthcare professionals
Mechanism of action
Estradiol is the principal intracellular human estrogen and is substantially more potent than estrone and estriol at the receptor level. It acts by binding to nuclear receptors in estrogen-responsive tissues (two receptors identified) and modulates pituitary LH and FSH secretion via negative feedback, reducing the elevated levels seen in postmenopausal women.
Labeled dosing
General adult dosing per the label: start with 0.0375 mg/day applied twice weekly for moderate to severe vasomotor symptoms or vulvar and vaginal atrophy due to menopause, with adjustment guided by clinical response; start with 0.025 mg/day for prevention of postmenopausal osteoporosis. Apply to the lower abdomen or buttocks, not the breasts. The final dose is determined by the prescribing doctor or pharmacist.
- Give continuously in women without an intact uterus; on a cyclic schedule (e.g., 3 weeks on, 1 week off) in women with an intact uterus
- When switching from oral estrogens, start 1 week after withdrawal, or sooner if symptoms reappear in under 1 week
- Attempt to taper or discontinue at 3 to 6 month intervals
- Consider adding a progestogen in women with a uterus to reduce endometrial cancer risk
- Use the lowest effective dose for the shortest duration and reevaluate periodically
- Most common adverse reactions (≥10%): headache, breast tenderness, nasopharyngitis, sinusitis, sinus headache, upper respiratory tract infection, back pain, depression, irregular vaginal bleeding or spotting
- No clinical trials were conducted with this system; it is bioequivalent to the original formulation
🎓 Key points for students
- Estradiol is the principal intracellular human estrogen and more potent than estrone and estriol
- After menopause, most estrogen comes from peripheral conversion of adrenal androstenedione to estrone
- Estrogens are partly metabolized by CYP3A4, so inducers and inhibitors alter levels
- Unopposed estrogen increases endometrial cancer risk in women with a uterus; adding a progestogen reduces it
- WHI findings were from oral CE 0.625 mg; relevance to other doses, routes, or products is not known
- Serum estrogen concentration does not predict an individual woman's therapeutic response or risk of adverse outcomes
EME runs your whole clinic: appointments with WhatsApp reminders, patient files, finance & inventory, a patient portal and a members-price medical store — with your data isolated and protected.
Try EME free How we protect your data❓ FAQ
What is the estradiol patch used for?
It is used to treat moderate to severe menopausal symptoms (such as hot flashes and vaginal symptoms), hypoestrogenism, and to prevent postmenopausal osteoporosis, as prescribed by a doctor.
Where should the patch be applied?
On a clean, dry area of the lower abdomen or buttocks. Do not apply it to the breasts. Apply it right after removing it from the protective pouch.
How do I dispose of a used patch?
Fold the sticky sides together, place it in a sturdy child-proof container, then in the trash. Do not flush it, since used patches still contain active hormone.
What are the common side effects?
Headache, breast tenderness, nose and sinus infections, back pain, depression, and irregular vaginal bleeding or spotting.
Who should not use this medicine?
Women with undiagnosed abnormal genital bleeding, current or past breast cancer, blood clots, stroke or heart attack, liver disease, known clotting disorders, or hypersensitivity to the product.
Can it be used during pregnancy or breastfeeding?
It is not indicated for use in pregnancy. During breastfeeding it can reduce milk production, so consult your doctor before use.
⚕️ For education only — not a substitute for advice from your doctor or pharmacist. Do not start or stop any medicine without advice. Source: official FDA drug label via openFDA (2024-05), simplified. Updated: 2026-11-15.